Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents.
about
The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.Temporal aspects of the action of ASA404 (vadimezan; DMXAA).Vascular targeted therapies in oncology.Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study.The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA).An update on the clinical development of drugs to disable tumor vasculature.The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice.Preliminary Evidence That High-Dose Vitamin C has a Vascular Disrupting Action in Mice.Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours.Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement
P2860
Q34122191-EFC2C75D-A936-4A0D-B9F3-5E356D0FD5E8Q35052189-508937D9-8548-4502-866E-59F322CDD4ACQ36641876-E8B09A06-6F5A-4D8A-87D8-2D84287126BFQ37254370-C62A2230-3E91-4965-8054-B47F34F64673Q37340510-2D881B2B-6ADB-4F2E-B5E3-AA68A16EC7B9Q37355059-DBAF1853-64B0-4591-AE3A-798EB4D94220Q37668618-C7284A4A-D296-46EF-A6D5-2A02B6DD226FQ37922775-F4175759-BA83-4F2E-9C1F-42B63A062952Q38088732-6B35EB84-C673-4E6B-8C20-A83D2F7C9F1DQ38289597-0CEE4ED6-96EA-4BE5-A6B8-36E05F4988FCQ42148903-68054E41-AC8C-4185-9BE9-963FC9CD9428Q43708720-447AABB1-80CC-4491-AA8F-7A201A5A2FF7Q56967593-9807E236-A9DE-4D94-ADEC-E56FB26D9876
P2860
Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Measurement of plasma 5-hydrox ...... action of antivascular agents.
@en
Measurement of plasma 5-hydrox ...... action of antivascular agents.
@nl
type
label
Measurement of plasma 5-hydrox ...... action of antivascular agents.
@en
Measurement of plasma 5-hydrox ...... action of antivascular agents.
@nl
prefLabel
Measurement of plasma 5-hydrox ...... action of antivascular agents.
@en
Measurement of plasma 5-hydrox ...... action of antivascular agents.
@nl
P2093
P1433
P1476
Measurement of plasma 5-hydrox ...... action of antivascular agents.
@en
P2093
P304
P356
10.1016/S0009-8981(01)00692-1
P577
2001-12-01T00:00:00Z